trending Market Intelligence /marketintelligence/en/news-insights/trending/_ZhWc9FJYpQFDF01UZWvSQ2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Kitov Pharma to implement 1-for-20 reverse stock split


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Kitov Pharma to implement 1-for-20 reverse stock split

Kitov Pharma Ltd said its shareholders approved a 1-for-20 reverse stock split of the company's share capital.

The Israeli drug developer said the split will reduce its share capital to 250 million ordinary shares and 50 million preferred shares.

The move will also reduce the issued and outstanding ordinary shares of the company to about 16 million ordinary shares.

After the stock split, the ordinary shares will start trading on the Tel Aviv Stock Exchange on Jan. 6 and the American depositary shares on the Nasdaq on Jan. 7.